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1. Introduction  
One of the most striking characteristic of the brain is its profuse neuronal connectivity. Not 
surprisingly, the function of the nervous system critically depends on the spatiotemporal 
pattern of intercommunication between different regions of the brain. Both macro- and 
microscopic aspects of the wiring diagrams of brain circuits are relevant and need to be 
understood in order to cope with the complexity of the brain function. In this way, for 
instance, the long-range connections that carry the functional specification of cortical 
territories need to be studied together with the detailed microcircuits inside a cortical 
column. Moreover, the temporal dimension of these wiring diagrams must be investigated 
since neuronal networks are dynamic structures exhibiting context-dependent changes in 
synaptic weights (Canals et al., 2009) and numbers (Chklovskii et al., 2004). Investigations 
over the last decades strongly suggest that stimulus or task related neural activity is 
distributed over large parts of the brain, covering different cortical and sub-cortical areas. 
For a detailed understanding of brain function, it is of prime importance to understand the 
organization of the neuronal connections. To chart the anatomical connections between the 
various components of brain networks, the neuronal tract tracing technique has been proved 
to be very useful. Thus, experimental tools that allow the exploration of brain circuits at 
                                                 
*Kirti Dhingra1,5, Ritu Mishra2,6, Almut Schüz1, Jörn Engelmann2, Michael Beyerlein1,  
Santiago Canals1,7 and Nikos K. Logothetis1,3 
1Department for Physiology of Cognitive Processes, Max-Planck Institute for Biological Cybernetics,  
Tübingen, Germany 
2High-Field MR Center, Max-Planck Institute for Biological Cybernetics, Tübingen, Germany 
3Imaging Science and Biomedical Engineering, University of Manchester, Manchester, England 
4Department of Chemistry, Durham University, South Road, Durham, England 
5Case Center for Imaging Research, Department of Radiology, Case Western Reserve University,  
Cleveland, OH,, USA 
6School of Biological & Biomedical Sciences, Durham University, South Road, Durham, England 
7Instituto de Neurociencias CSIC-UMH, Campus de San Juan, San Juan de Alicante, Spain 
www.intechopen.com
 
Neuroimaging – Methods 
 
182 
diverse organizational levels are mandatory for the understanding of brain 
intercommunication and information processing. 
Magnetic Resonance Imaging (MRI) has great potential for mapping brain connectivity 
(Koretsky and Silva, 2004). It is a noninvasive volume imaging technique that can be applied 
longitudinally to the same subject, capturing the temporal dimension of brain connections 
and providing complete descriptions of large-scale three-dimensional (3-D) neuronal 
networks. The main limitation of MRI is its low sensitivity. To compensate for weak signals 
in MRI, efforts have been focused on the development of MR contrast agents. Recently, the 
paramagnetic ion manganese (Mn2+) has been introduced as a MR-contrast agent for 
investigating in vivo neuronal connectivity (Canals et al., 2008; Pautler et al., 1998). 
Following the general mechanism of other classical anterograde tracers, Mn2+ is taken up by 
neurons and transported to the distant synaptic terminals where it accumulates and reveals 
the projection fields (Canals et al., 2008; Leergaard et al., 2003; Murayama et al., 2006; 
Pautler et al., 1998; Saleem et al., 2002; Sloot and Gramsbergen, 1994; Tjalve et al., 1995; Van 
der Linden et al., 2002; Watanabe et al., 2004), thus delineating brain connectivity. In 
contrast to classical tracers, which require processed fixed tissue for data analysis, neuronal 
tracing with Mn2+ as an MR tracer is performed in vivo. 
However, cellular toxicity is an important drawback that challenges the applicability of 
Mn2+-enhanced MRI (MEMRI). It has been shown that Mn2+ can be cytotoxic at 
concentrations used for neural tracing (Canals et al., 2008; Chandra et al., 1981; McMillan, 
1999; Pal et al., 1999). Additional disadvantages of this technique are its high diffusion at the 
injection site, which challenge the specificity of the resulting projections, and its 
incompatibility with other visualization systems (Canals et al., 2008). If Mn2+ toxicity is not 
counteracted, it generates such perturbations in the neuronal circuits under study that 
eliminate the advantage of using Mn2+ as an in vivo neuronal tracer. In addition, at the end 
of an in vivo connectivity experiment using a paramagnetic tracer, it could be very 
informative to analyze the laminar and subcellular distribution of the neuronal connections. 
Such an experiment cannot be performed by using current MEMRI methods. New non-toxic 
paramagnetic tracers with anterograde, but also retrograde capabilities (i.e. when the tracer 
moves from the terminal ends to the soma identifying the origin of a synaptic contact) are 
desirable, particularly for functional studies, for quantitative 3-D analysis of connectivity, or 
for repetitive applications investigating the same pathway dynamically over time. 
Here we report a strategy to produce neuronal tract tracers with paramagnetic properties, 
biochemical stability and biocompatibility. The new tracers are imbued with double 
functionality in a single molecule that allows both in vivo longitudinal brain connectivity 
studies by means of MRI and postmortem subcellular investigation in the same 
experimental animal. Therefore, the macro- and microscopic aspects of a brain circuit can be 
simultaneously investigated.  
As a proof of concept we focused on the well-known neuroanatomical tracer biocytin which 
is taken up by neurons and transported in both antero- and retrograde directions (King et 
al., 1989). Several characteristics make biocytin a good tracer model. It has been used in 
numerous tracing studies, both after intracellular or extracellular application, and much is 
known about its biophysical properties (Horikawa and Armstrong, 1988). Due to its high 
affinity to avidin, it can be visualized by using a host of avidin conjugated markers at the 
light- and electron microscopic level. Extracellular application of biocytin results in very 
well localized injection sites with no uptake by fibers of passage or glial cells. These two last 
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characteristics result in a high specificity of biocytin tracings (Kita and Armstrong, 1991; 
Lapper and Bolam, 1991; Wirsig-Wiechmann, 1994). 
Structurally, biocytin consists of D-Biotin and L-lysine connected via an amide bond which 
is susceptible to cleavage by biotinidase enzyme. Biotinidase is the enzyme mainly 
responsible for recycling of the vitamin biotin by cleaving biocytin and biotinylated 
peptides/proteins (Hymes and Wolf, 1996; Mock et al., 1999; Wilbur et al., 1996). Biotinidase 
plays an important role in brain function (Pispa, 1965; Suchy et al., 1985). A deficiency in the 
biotinidase enzyme has been linked to several neurological disorders (Heller et al., 2002; 
Tsao and Kien, 2002; Zaffanello et al., 2003). For this reason, biocytin has relatively small 
half life in vivo, which forces short post injection survival times and increases the probability 
of only partial reconstruction of neuronal projections. Using the same strategy, we recently 
introduced two new biocytin-based neuroanatomical tracers [aminopropyl-biocytin and serine-
biocytin; Scheme 1] with improved enzymatic stability (Mishra et al., 2009). The in vivo 
results for these two derivatives of biocytin demonstrated that they are biochemically stable 
conjugates, retain full tracing capabilities and more importantly these molecules allow 
longer post-injection survival times due to the improved stability and therefore, provide 
more detailed and complete connectivity information. The commercial biocytin was totally 
degraded 96 h postinjection, however, these improved neuronal tracers still stained 
neuronal cell bodies and fibers at the injection site and remote terminal fields. These 
improved neuronal tracers present an edge over conventional histological procedures, as 
their better stability could reduce the problems related to the endogenous degradation of the 
tracer molecule before the animal is sacrificed. As was suggested in the previous work 
(Mishra et al., 2009), the applicability of these new agents could be further diversified by 
coupling with different reporter moieties and utilized for multimodal tracing. For instance, 
the combination of reported molecules with MR reporters could serve as a tool for magnetic 
resonance imaging and, hence, be used for visualizing brain connectivity in vivo. 
Here in, we have followed up our previous investigations and developed two novel and 
structurally distinct gadolinium (Gd3+) containing biocytin-based multimodal neuronal 
tracers ([Gd.L1] and [Gd.L2]) (Scheme 1). The backbone of these structures were 
functionalized by covalently linking the kinetically stable gadolinium caged organic 
macrocyclic moiety [DOTA and DO3A-serine] as MR reporters to perform in vivo 
longitudinal brain connectivity studies by means of MRI, leaving α-position of lysine moiety 
free for internalization in neurons and biotin moiety free for avidin binding for subsequent 
visualization with postmortem microscopic histological methods.  
The first MR tracer [Gd.L1] was derived from the recently published stable biocytin variant 
aminopropyl-biocytin (Mishra et al., 2009), whereby [Gd.DOTA] was coupled to aminopropyl-
biocytin via an amide bond. The second MR tracer, [Gd.L2] consists of a new precursor 
[Gd.DO3A-serine] which has an orthogonal amine and a carboxylate group on the fourth 
nitrogen of [Gd.DO3A] for the coupling of biotin and lysine, respectively. By replacing 
[Gd.DOTA] with FITC in [Gd.L1] fluorescently labeled aminopropyl-biocytin [Fluo.L1] was 
obtained for fluorescence microscopy studies.  
We present data that demonstrate the validity of the approach by showing cortical 
connectivity in vivo applying T1-weighted MR-imaging. In addition, the corresponding 
subcellular details, fibers and neuronal morphology under light microscopy were 
investigated in the same experimental animals by means of avidin-biotin interactions and 
conventional histological techniques.  
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Scheme 1. Structures of studied biocytin-derived neuroanatomical tracers. 
2. Results and discussion  
2.1 Synthesis of ligands and complexes 
Two structurally different Gd3+ complexing neuroanatomical tracers ([Gd.L1] and [Gd.L2]; 
Scheme 1) were designed and synthesized. These conjugates enclosed the [Gd.DO3A] 
construct as an MR reporter and biotin to be used for microscopic visualization by means of 
histological techniques.  
The first MR tracer [Gd.L1] was derived from stable biocytin variant, propylamine-biocytin 
(Mishra et al., 2009), where [Gd.DOTA] was coupled to aminopropyl-biocytin via amide 
bond. [Gd.L1] was synthesised in seven steps prior to complexation with Gd3+ (Scheme 2). 
Propylamine-biocytin 6 was synthesized in three steps, starting with the reaction of 
acrylonitrile on αN-carbobenzyloxy-L-lysine methyl ester giving cyano compound 4. 
Propinonitrile derivative 5 was obtained after coupling acid D-biotin with the secondary 
amine of 4 by using PyBroP as a coupling reagent and diisopropylethylamine as the base in 
anhydrous CH2Cl2. Subsequent selective reduction of nitrile groups in the presence of Ra-
Ni, H2, 7M NH3/MeOH yielded amine intermediate 6. The macrocycle intermediate 3 (tris-
tert-butyl-DOTA) was obtained in two steps by stepwise alkylation of tris-tert-butyl-DO3A, 
1, with benzylbromoacetate in acetonitrile generating 2, and following deprotection of 
benzyl groups produced the corresponding acid 3 in high yield (Pope et al., 2003). Then, 
tetra-ester 7 was synthesized by coupling of amine 6 and acid 3 [EDC/HOBt/NMM] in 
anhydrous DMF, from which L1 was obtained by successive deprotections (benzylcarbamate 
removal by hydrogenation using Pd-C as the catalyst, methyl group with LiOH and tert-
butyl groups with neat TFA). 
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Scheme 2. Reagents and conditions: (i) benzylbromoacetate, MeCN, K2CO3, 100ºC; (ii)  Pd-C 
(10%), H2, MeOH, 50 psi; (iii) acrylonitrile, TEA, MeOH; (iv) Biotin, PyBroP/DIPEA/CH2Cl2; 
(v) Ra-Ni, H2, 7 M NH3/MeOH, 50 psi; (vi) NMM/EDC/HOBt/DMF; (vii) LiOH, 
THF:MeOH:water (3:2:2); (viii) TFA (neat). 
The second MR tracer, [Gd.L2] consists [Gd.DO3A-serine] which has an orthogonal amine 
and a carboxylate group available on the fourth nitrogen of [Gd.DO3A] for the coupling of 
biotin and lysine, respectively. [Gd.L2] was synthesized in 9 steps prior to complexation 
with Gd3+ (Scheme 3). Bromination on the hydroxyl group of N-carbobenzyloxy-L-serine 
methyl ester yielded 8. The bromination reaction was run for no more than 30 min. This 
avoided the formation of allyl analogues of the product by elimination of bromine. The most 
reasonable route to synthesize ligand 10 was by alkylation of 8 on 1 but the elimination of 
the bromine group under highly basic conditions resulted in starting compound together 
with allyl side product. An alternative route was taken to obtain 10 where monoalkylated 
intermediate 9 was generated by alkylation of excess cyclen with 8 in anhydrous toluene, 
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which was further alkylated by tert-butylbromoacetate yielding 10. Mono-acid 11 was 
obtained by mild hydrolysis of the methyl ester in the presence of LiOH, which was further 
coupled to amine of Boc-Lys-OMe [EDC/HOBt/NMM] in anhydrous DMF to produce 12. 
The benzylcarbamate was hydrogenated over Pd/C to yield the secondary amine 13 which 
was coupled to acid D-biotin [EDC/HOBt/NMM] in anhydrous DMF to give tetra-ester 14. 
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Scheme 3. Reagents and conditions: (i) NBS/PPh3/DMF; (ii) cyclen/toluene; (iii) tert-butyl 
bromoacetate/Na2CO3/MeCN; (iv) LiOH, THF:MeOH:H2O (3:2:2); (v) Boc-Lys-OMe, 
NMM/HOBt/EDC/DMF; (vi) Pd-C (10%), H2, MeOH, 50 psi; (vii) biotin, 
HATU/DIPEA/DMF; (viii) TFA (neat). 
Carboxylic acid derivative L2 was obtained by successive deprotections (first the methyl 
group with LiOH and then tert-butyl groups with neat TFA). 
Ligands, L1 and L2, were purified by RP-HPLC and loaded with Gd3+ using GdCl3.6H2O in 
water at pH 6.5. The final concentration of Gd3+ was determined by inductively-coupled 
plasma optical emission spectrophotometry (ICP-OES). 
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2.2 Proton relaxivity modulation of [Gd.L
1
] and [Gd.L
2
] by biotin-avidin interaction 
The extensive applications of biotin-avidin interactions have been found attractive in 
biomolecule detection, medical diagnostics, immunoassays and nanoscience (Bickel et al., 
2001; Cao et al., 2003; Caswell et al., 2003; Rivera et al., 2003; Weizmann et al., 2003). Due to 
the high affinity of biotin to tetrameric avidin, biotinylated compounds can be visualized by 
light microscopy in postmortem tissues using avidin-conjugated markers. To investigate 
and quantify the binding behavior of the two contrast agents (CAs) to avidin which is 
important for the histological detection, we performed MRI experiments at 7T (300 MHz) 
[phosphate buffered saline (PBS), 7.4 pH, 23°C] with increasing concentrations of avidin 
proportional to constant concentrations of CAs (0.25 mM) and measured the proton 
longitudinal relaxivities (r1p).  
The proton longitudinal relaxivities (r1p) of [Gd.L1] and [Gd.L2] at 7T (300 MHz) [phosphate 
buffered saline (PBS), 7.4 pH, 23°C] were found to be 5.52±0.08 mM–1 s–1 and 7.27±0.13 mM–1 
s–1, respectively. As anticipated, [Gd.L1] shows similar relaxivity to [Gd.DOTA] complexes. 
However [Gd.L2] shows higher relaxivity than that reported in the literature for Gd-DO3A 
derivatives in such a physiological solution (Caravan et al., 1999). The observed higher 
relaxivity in solution is explained by the high molecular volume and a significant second-
sphere contribution through amide moieties close to the paramagnetic proximity present in 
the molecule (Aime et al., 1996; Botta, 2000).  
 
Complexes 
r1p (mM-1s-1) 
Change (%) 
[Gd.Ln] [Gd.Ln]:avidin 
[Gd.L1] 5.52±0.08 6.10±0.11 +11 
[Gd.L2] 7.27±0.13 6.65±0.09 -9 
Table 1. Relaxivity (r1p, mM-1s-1) for [Gd.L1]/[Gd.L2] and [Gd.L1]/[Gd.L2]:avidin complexes 
(23°C, 7T (300 MHz), pH 7.4, PBS, 0.25 mM complex). 
Inevitable, r1p of [Gd.L1] was slightly increased (11%) in contrast to [Gd-L2] (9% decreased) 
upon binding to avidin (Table 1). This is in reference to the Solomon–Bloembergen–Morgan 
theory envisaging that at high magnetic fields, the longitudinal proton relaxivity changes with 
the opposite of molecular rotational correlation time (τR) suggesting that relaxivity change 
should be expected upon binding of the CAs to macromolecules (Livramento et al., 2006). The 
saturation in r1p at a ratio approximately at 2:1 (assuming a 2:1 stoichiometry of interaction) for 
the [Gd-L1]/[Gd-L2]:avidin adduct was obtained which clearly indicating similar steric 
hindrance of both CAs. These results suggest that [Gd.L1] and [Gd.L2] block the adjacent 
binding sites of biotin but evidently fit into two opposite binding pockets of avidin. The 
complexes {[Gd.L1]/[Gd.L2]:avidin} (2:1) binding stoichiometry reveal that [Gd.L1] and 
[Gd.L2] could be visualized by binding with avidin via histological techniques. However, an 
improved visualisation is expected if binding occurred to all pockets of avidin in a 4:1 ratio.  
2.3 In vitro cell culture studies  
It is well known from the literature that biocytin is a low molecular weight compound 
which has excellent uptake and transport capability in neuronal cells. Biocytin could be used 
as antero- as well as retrograde neuronal tract-tracer after intra- and extracellular injection in 
the brain (Kobbert et al., 2000). However, the uptake mechanism of biocytin at higher 
concentrations is not well known. A rapid and sodium/potassium-dependent high affinity 
uptake of biocytin in NB2a neuroblastoma cells was reported by Baur et al. This uptake was 
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very specific and selective to NB2a neuroblastoma cells as compared to C6 astrocytoma cells 
(Baur et al., 2002). Saturation kinetic of biocytin in a low concentration range was reported. 
However, the biocytin concentration in the brain is well below the reported concentration at 
half maximal saturation (Km) of the biocytin uptake under physiological conditions (Baur et 
al., 2002). In contrast, after pressure or iontophoretic injection, local concentrations exceed 
the physiological concentration of biocytin manifold. Thus, the uptake mechanism under 
such conditions is not yet established.  
The Gd-chelated macrocyclic modified biocytin molecules, [Gd.L1] and [Gd.L2], are high 
molecular weight compounds as compared to biocytin alone. We investigated the cellular 
internalization of these compounds and their ability to enhance the MR contrast in vitro. For 
these studies murine N18 neuroblastoma cells were used as cellular model. In order to 
induce more neuronal metabolic and morphologic features in these tumor cells, serum 
deprivation was used to differentiate the cells (Marchisio et al., 1979). During the slow 
stepwise reduction of FBS content in the culture medium to 0.625% the growth rate slowed 
down and cells started to show a neuronal morphology with a network of neurite-like 
cellular processes which were completely absent at 10% FBS. Similar in vitro studies were 
also performed with the FITC containing aminopropyl-biocytin [Fluo.L1]. All cell incubations 
were performed in HBSS/10 mM HEPES buffer for 6 hours. 
2.3.1 In vitro studies of cellular toxicity on N18 murine neuroblastoma cells  
We first tested whether the contrast agents would have an adverse effect on differentiated 
N18 cells. For this purpose cells were incubated with [Gd.L1] or [Gd.L2] for 6 h in HBSS/10 
mM HEPES and the number of cells were determined by fluorescence spectroscopy using 
the DNA dye Bisbenzimid Hoechst 33342. Only [Gd.L2] showed a significant cytotoxic effect 
at 50 µM (Figure 1). Thus, all further experiments were done at concentrations below this 
level (40 and 20 µM for [Gd.L1] and [Gd.L2]). 
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Fig. 1. Evaluation of the acute short term toxicity of [Gd.L1] and [Gd.L2]. Differentiated N18 
neuroblastoma cells were incubated with the indicated concentration of [Gd.L1] or [Gd.L2] 
in HBSS/10 mM HEPES for 6h. Afterwards DNA dye Bisbenzimide Hoechst 33342 was 
added for 30 min in complete cell culture medium to determine the number of cells by the 
fluorescence of the dye/DNA conjugate (Ex 355nm/Em 465 nm). Values represent 
mean±SEM (n=6-12). ***p< 0.001, statistically different compared to control  
(ANOVA, Dunnett´s multiple comparison test). 
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2.3.2 Fluorescence microscopy to detect internalization and subcellular distribution 
Since the intracellular distribution of [Gd.L1] and [Gd.L2] cannot be directly detected by 
MRI, the fluorophore containing analogue to [Gd.L1], [Fluo.L1] was used. Fluorescence 
microscopy of living cells displayed a detectable uptake of the compound into 
morphologically differentiated N18 cells. Figure 2 shows the cellular localization of [Fluo.L1] 
after incubation with 50 µM for 12 h and subsequent washing and quenching of remaining 
extracellular fluorescence by Trypan Blue. [Fluo.L1] (green fluorescence of the covalently 
linked FITC) was internalized very quickly and mainly accumulated in vesicles in the 
perinuclear region (nuclei counterstained in blue) of the cells. Green fluorescence of 
[Fluo.L1] could also be detected in the projections of the cells. These results indicate a 
predominantly endosomal uptake of [Fluo.L1] into morphologically differentiated 
neuroblastoma cells. The optical evidence that [Fluo.L1] was also detected along the 
processes of the cells set grounds for possible application of synthesized compounds as tract 
tracers. 
 
 
Fig. 2. Optical evidence for intracellular localization of [Fluo.L1] in N18 neuroblastoma cells. 
Cells were incubated with 50 µM of [Fluo.L1] for 6 h in HBSS/10 mM HEPES as described in 
materials and methods. Overlay of green (FITC in [Fluo-L1]) and blue fluorescence  
(DNA dye Hoechst 33342) (left) and in addition of the phase contrast image (right). 
2.3.3 MRI studies on N18 murine neuroblastoma cells 
After proving the cellular uptake, the ability of [Gd.L1] and [Gd.L2] to enhance contrast in 
MR images of labeled cells was tested. For this purpose differentiated N18 cells were 
incubated with either 20 or 40 µM of [Gd.L1] or [Gd.L2], respectively. After removal of the 
incubation medium of all samples the labeled cells were extensively washed with buffer. A 
constant number of treated cells were transferred into 0.5 mL Eppendorf tubes and cells 
were allowed to settle down. T1-weighted images were taken and the values of longitudinal 
(T1) relaxation times were measured in an axial slice of cell pellets and supernatant at 3T and 
room temperature. 
Figure 3 shows representative examples of T1-weighted images achieved after incubation 
with 20 or 40 µM of [Gd.L1] or 40 µM of [Gd.L2]. A significant contrast enhancement could 
be observed in the images for both compounds compared to control cells incubated in the 
absence of contrast agent. The determination of apparent cellular relaxation rate R1,cell 
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(=1/T1,cell) in the cell pellet confirmed these results (Figure 4). The significance levels here 
were lower since averages of independent experiments were taken. 
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Fig. 3. Examples of T1-weighted MR images of differentiated N18 neuroblastoma cells and 
analysis of the signal intensities in these images. Cells were incubated with 20 or 40 µM 
[Gd.L1] (A) or 40 µM of [Gd.L1] and [Gd.L2] (B) for 6 h in HBSS/10 mM HEPES. Cells were 
washed, trypsinized and resuspended in fresh culture medium (without CA) at a cell 
density of 1×107 cells/500 µL and transferred into 0.5 mL tubes. Cells were allowed to settle 
prior to MR experiments for imaging and determination of T1 values in an axial slice 
through the cell pellet. Parameters for MRI are given in the experimental part. The bar 
graphs resulted from the pixelwise evaluation of signal intensity in the corresponding 
images. Values represent mean±SD (n=37 (A) and 44 (B)); ***, p>0.001, significantly different 
to control, a, p<0.05 and c, p>0.001, significant difference between 20 µM, 40 µM and 
[Gd.L1], [Gd.L2], respectively (ANOVA, Tukey´s multiple comparison test). 
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Fig. 4. Cellular relaxation rate R1,cell of differentiated N18 neuroblastoma cells. Values 
represent mean±SEM (n=2-5); **, p>0.01, *, p>0.05 significantly different to control 
(ANOVA, Dunnett´s multiple comparison test). 
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2.4 In vivo uptake and transport: MR and histology studies of [Gd.L
1
] and [Gd.L
2
] in 
rat brain 
In the final step, we investigated the tracing abilities of these newly synthesized imaging 
probes, [Gd.L1] and [Gd.L2], by means of MRI and classical histological methods in the same 
experimental animal. We performed a series of pressure and iontophoretic injections into 
the primary motor cortex (M1) of anaesthetized albino rats (Sprague Dawley) and evaluated 
the transport of these compounds at 24 and 48 h post-injection (see methods section for 
technical details). After the local injection of [Gd.L1] in the primary motor cortex of the rat, 
the target area was visualized in T1-weighted MRI as a large increase in signal (due to the 
decrease of the T1 relaxation time; Figure 5A). Statistical analysis comparing baseline images 
(acquired either before or immediately after the injection) with images acquired after 24 and 
48 h revealed a significant increase in T1-weighted signal intensity in various brain regions 
 
 
Fig. 5. In vivo neuronal tract tracing with [Gd.L1]. Neuronal connections of the primary 
motor cortex M1 of the rat were investigated. (A) Coronal T1-weighted images acquired 30 
min after the injection of [Gd.L1] in M1. Note the enhanced signal (asterisk) at the injection 
site. The inset shows a representative scheme of rat brain anatomy at the coordinates of the 
injection (Paxinos and Watson, 2007). (B) Shown are six coronal MR images illustrating the 
distribution of [Gd.L1] signal in the brain after an injection in M1. The presence of signal is 
shown as statistical maps (unpaired t test; p<0.01) comparing the baseline (pre-injection 
scans) and scans acquired 48 h later, superimposed on the anatomical images. The results 
demonstrate local increases in signal due to [Gd.L1] injection and long-range neuronal tract-
tracing after 48 h in the striatum (1-4) and thalamus (5-6). After the last MRI session, the 
animal was euthanized and the histology is shown in Figure 6.  
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far away from the injection site. For instance, statistically significant increases in signal 
intensity were detected in the thalamus and the homologous contralateral M1 cortex (Figure 
5B), areas that are well known to be connected with M1, suggesting that the tracer has 
actually been taken up by neurons in vivo and transported in the axons. This result 
corroborates the neuronal-tracing ability of [Gd.L1] and its suitability for in vivo studies of 
brain connectivity. The MRI results obtained with [Gd.L2], after injection into the M1 cortex, 
showed a comparable pattern of neural connections as in [Gd.L1] (data not shown).  
 
 
Fig. 6. Histological stain of the same brain as shown in Fig. 5, 48 h after an iontophoretic 
injection with [Gd.L1]. Neurons at the injection site (A) have been stained. (B) Slightly 
stained fibres in the striatum bundles. The sections were counterstained with methyl green, 
visualizing cell bodies in the background. Bars: 100 µm. 
Biocytin is a powerful tracer for visualizing connections with histological techniques. In a 
previous paper (Mishra et al., 2009) we have shown that both kinds of modified biocytin, 
aminopropyl and serine biocytin, are well suited for tracing and have, in addition, the 
advantage of being considerably more stable than the biocytin itself. We further investigated 
the post-mortem tissue sections of the same MR experimental animals. However, no stain 
could be seen in the case of [Gd.L2], and in case of [Gd.L1] the stain was restricted to places 
where the concentration is usually strongest, i.e. to the injection site and the striatum 
bundles (Figure 6). This could be explained by an impaired reaction with the avidin 
peroxidase-DAB (3,3′-Diaminobenzidine) cocktail, necessary for histological staining. This 
can be concluded from the fact that our in vitro uptake studies on N18 murine 
neuroblastoma cells clearly revealed that these probes were taken up well by neurons even 
at low concentrations. The lower modulation of proton longitudinal relaxivity upon avidin 
binding of [Gd.L1] and [Gd.L2] (assuming a 2:1 stoichiometry of interaction) suggested that 
the interaction with avidin was strongly impaired. To further rule out the lack of uptake 
and/or transport and support the MRI findings, similar behavior was obtained after in vivo 
injections of [Fluo.L1] into the primary motor cortex (M1) of anaesthetized albino rats and 
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evaluation of the transport of this compound 24 h post-injection. We observed by 
fluorescence microscopy that [Fluo.L1] had been taken up by neurons (Figure 7), but we 
could not detect any stain in the same section using the staining technique depending on the 
biotin-avidin peroxidase-DAB (3,3'-Diaminobenzidine) cocktail.    
It is conceivable that the modifications introduced in the model modified biocytin 
(aminopropyl and serine biocytin) described above, together with the significant increase in 
molecular weight by about a factor of 2.5, sterically hinder the staining with avidin 
peroxidase-DAB cocktail in cells substantially, but retain the uptake and transport 
properties of the resulting contrast agent.  
 
 
Fig. 7. Injection site in the motor cortex of a rat, 24 h after injection with [Fluo.L1]. 
It can be seen that the neurons have taken up the tracer. Under transmission light, no stain 
could be seen, although the same section had undergone an avidin-biotin reaction. Bar 50 µm. 
3. Conclusion  
In summary, we present data on the functionalization of biocytin, a well known neuronal 
tract tracer, and demonstrate the validity of the approach by showing cortical connectivity 
in live rats with the help of MRI. Our study offers a new platform for the development of 
multimodal molecular imaging tools for brain connectivity studies in vivo. 
4. Materials and methods 
4.1 Chemicals 
All solvents and reagents were purchased at analytical grade from commercial suppliers 
(Acros, Aldrich, Fluka, Merck, Strem and VWR) and were used without further purification 
unless otherwise stated. All air- or water-sensitive chemicals were stored under an inert 
atmosphere. Ultra pure de-ionised water (18 MΩ cm-1) was used throughout.  
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4.2 Chromatography 
Flash column chromatography was performed using flash silica gel 60 (70-230 mesh) from 
Merck. Thin layer chromatography (TLC) was performed on aluminum sheet silica gel 
plates with 0.2 mm thick silica gel 60 F254 (E. Merck) using different mobile phases. The 
compounds were visualized by UV irradiation (254 nm) or iodine staining. Reverse phase 
HPLC was performed at room temperature on a Varian PrepStar Instrument, equipped 
with PrepStar SD-1 pump heads. UV absorbance was measured using a ProStar 335 
photodiode array detector at 214 nm. Analytical RP-HPLC was performed in a stainless 
steel Chromsep (length 250 mm, internal diameter 4.6 mm and particle size 8 µm) C18 
column and semi-preparative RP-HPLC was performed on a stainless steel Chromsep 
(length 250 mm, internal diameter 21.2 mm and particle size 5 µm) C18 column (Varian). 
The compounds were purified using one of the following two methods. Method A: 
gradient with the mobile phase starting from 95% solvent A (H2O) and 5% of solvent B 
(MeOH) to 70% B in 10 min, 90% B in 18 min, 90% B isocratic till 24 min and decreased to 
5% B in 28 min. Method B: 95% solvent A (H2O, 0.1% HCOOH) and 5% solvent B 
(acetonitrile, 0.1% HCOOH) to 70% solvent B in 10 min and then to 100% in the next 8 min 
running isocratic for 12 min and then back to 5% solvent B in the next 2 min. The flow rate 
generally used for analytical HPLC was 1 mL/min and for semi-preparative HPLC 15 
mL/min. All the HPLC-grade solvents for HPLC were filtered through a nylon-66 
Millipore filter (0.45 µm) prior to use. 
4.3 Spectroscopy 
1H NMR and 13C NMR spectra were recorded on Bruker DRX250 and DRX400 spectrometers 
at room temperature. The 1H NMR chemical shifts were adjusted to the residual protons of 
the solvent peaks which were referenced to TMS (0.0 ppm), and 13C NMR chemical shifts 
were referenced to CDCl3 (77.0 ppm).  
Electrospray ionization mass spectra (ESI-MS in positive and negative ion mode) were 
performed on an ion trap SL 1100 system (Agilent) and High Resolution (HR) mass spectra 
were measured on Bruker Daltonics Apex II FT-ICR-MS (Bruker).  
Inductively coupled plasma optical emission spectrometry (ICP-OES) for the evaluation of 
the Gd3+ concentration was performed using a Jobin–Yvon Ultima 2 spectrometer. 
4.4 In vitro MR tube measurements 
Longitudinal and transverse relaxation times (T1 and T2) of the [Gd.L1] and [Gd.L2] were 
examined using a vertical 7T (300 MHz)/60-cm diameter bore magnet (Bruker BioSpin). 
Four different concentrations (1 mM, 0.75 mM, 0.5 mM, 0.25 mM) of [Gd.L1] and [Gd.L2] 
were prepared in Phosphate-Buffered-Saline (PBS) in 1.5 mL Eppendorf tubes at 
physiological pH to measure relaxivity. Each tube was filled with 400 µl of the CA solution. 
The y-axis intercept of the linear regression plot of the relaxation rate obtained for these 
tubes with the corresponding concentration of CA gave the diamagnetic relaxation rate 
(1/Td).  
To measure the changes in r1 and r2 upon binding to avidin, MRI experiments were 
performed with increasing concentrations of avidin proportional to a constant concentration 
of [Gd.L1] and [Gd.L2] (0.25 mM) incubated for 1 h at 37°C. The stock solution of avidin (1 
mM) was prepared in PBS at pH 7.4. 
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Axial images were obtained for the set of tubes at 7T and the T1/T2 values were then 
calculated. 
Relaxivity at different concentrations of avidin was then calculated using equation [1]. 
 r1,obs = (1/T1,obs-1/T1,d) / [Gd.Ln]  (1) 
where T1,obs is the measured T1, T1,d is the diamagnetic contribution of the solvent (calculated 
to be 2400 - 2700 ms) and [GdLn] is the concentration in mmol/L of the appropriate Gd(III) 
complex (n = 1-2).  
4.5 Synthesis of ligands and tracers 
(S)-methyl 3,15-dioxo-10-(5-((3aR,4R,6aS)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoyl)-1-phenyl-16-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)-2-oxa-4,10,14-triazahexadecane-5-carboxylate (7). A solution of 
compound 6 (0.3 g, 0.52 mmol), NMM (0.12 mL, 1.0 mmol) and HOBt (0.11 g, 0.57 mmol) in 
anhydrous DMF (15 mL) was stirred at 0-5˚C for 15 min and then EDC (0.08 g, 0.57 mmol) 
was added. The reaction mixture was stirred overnight at room temperature. Completion of 
the reaction was verified by ESI-MS, the solution was poured into water (50 mL) and 
extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered and the filtrate evaporated under reduced pressure. The residue was 
purified by column chromatography (silica gel, 10% MeOH in CH2Cl2, Rf = 0.15) to give 7 as 
a yellow gum (0.28 g, 48%). 1H NMR (CDCl3, 250 MHz), δ (ppm): 1.10-1.30 (m, 2H); 1.42 (s, 
18H); 1.52 (s, 10H); 1.60-1.95 (m, 12H); 2.03 (br s, 2H); 2.34 (br s, 3H); 2.62-2.99 (m, 6H); 3.32-
3.94 (m, 20H); 3.76 (br s, 6H); 3.94-3.98 (m, 2H); 4.23-4.43 (m, 2H); 4.47-4.63 (m, 1H); 5.12 (s, 
2H); 5.48-5.77 (m, 1H); 7.29-7.43 (m, 5H). ESI-MS (+): calcd C56H93N9O13S: m/z 1133.5 
(M+H)+; found 1133.2 (M+H)+. 
[4,7-Bis-carboxymethyl-10-(2-(3-(N-((S)-5-amino-5-carboxypentyl)-5-((3aR,4R,6aS)-2-oxo-
hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)propylamino)-2-oxoethyl)-
1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid (L1). A solution of compound 7 (0.25 g, 0.22 
mmol), 10% Pd-C (0.07 g) and H2 (50 psi) in MeOH (20 mL) was stirred at room temperature 
in Parr-apparatus for 8 h. Completion of the reaction was verified by ESI-MS, the solution 
was filtered through a G-4 sintered funnel, and the filtrate was evaporated under reduced 
pressure. This crude product was further dissolved in TFA (20 mL) and stirred overnight at 
room temperature. TFA was evaporated under reduced pressure. A solution of crude 
product in THF:MeOH:water (3:2:2) (10 mL) was stirred at 0-5˚C for 15 min and then LiOH 
(0.11 g, 4.7 mmol) was added. The reaction mixture was stirred for 2 h at room temperature. 
Completion of the reaction was verified by ESI-MS, the solvent was evaporated under 
reduced pressure and the residue was purified by preparative HPLC (tR = 3.8 min). After 
lyophilization, L1 was obtained as a light yellow sticky solid (0.1 g, 56%). 1H NMR (D2O, 250 
MHz), δ (ppm): 1.20-2.16 (m, 16H); 2.47 (t, J=7.0 Hz, 2H); 2.70-3.90 (br. m, 32H); 4.40-4.53 (m, 
1H); 4.24-4.28 (m, 1H). 13C NMR (D2O, 62.9 MHz), δ (ppm): 24.9; 27.8; 28.2; 30.5; 30.9; 32.8; 
35.0; 39.7; 42.4; 46.2; 47.9; 48.4; 50.7; 50.9; 51.2; 53.2; 53.8; 57.1; 58.1; 58.6; 63.0; 64.8; 164.2; 
165.3; 167.2; 177.1; 178.0; 178.8. ESI-MS (+): calcd C35H61N9O11S: m/z 816.4 (M+H)+; found 
816.3 (M+H)+. 
Methyl 2-(benzyloxycarbonylamino)-3-bromopropanoate (8). N-carbobenzyloxy-L-serine 
methyl ester (2 g, 8 mmol) and PPh3 (4 g, 16 mmol) were added in 50 ml anhydrous DMF. 
www.intechopen.com
 
Neuroimaging – Methods 
 
196 
Finally N-bromosuccinimide (2.8 g, 16 mmol) was added in small aliquots to the reaction 
mixture. The mixture was stirred for 30 minutes at 50 °C. Heating bath was removed and 2 
ml of MeOH was added to quench the reaction. 100 ml of ether was added and the reaction 
mixture was extracted with 100 ml water. The organic layer was dried over anhydrous 
Na2SO4, concentrated under vacuum and purified by column chromatography (silica gel, 
30% EtOAc in n-hexane) to give 8 as a yellow gum (2.1 g, 84%).  1H NMR (CDCl3, 400 MHz), 
δ (ppm): 3.40-3.70 (m, 5H); 4.57-4.62 (m, 1H); 4.91 (s, 2H); 5.49-5.58 (m, 1H); 7.07-7.28 (m, 
5H). 13C NMR (CDCl3, 100 MHz), δ (ppm) 33.6; 53.0; 54.2; 67.2; 128.0; 128.2; 128.4; 139.5; 
159.5; 169.2. ESI-MS (+): calcd C12H14BrNO4: m/z 317.1 (M+H)+ and found 317.3 (M+H)+. 
Methyl 2-(benzyloxycarbonylamino)-3-(1,4,7,10-tetraazacyclododecan-1-yl)propanoate (9). 
Compound 8 (0.6 g, 1.9 mmol) in 25 ml of toluene was added dropwise to the solution of 
cyclen (2g, 11.6 mmol) in 100 ml of toluene at room temperature. The reaction mixture was 
refluxed for 18 h. The reaction mixture was cooled, filtered through a G-4 sintered funnel; 
filtrate was evaporated under reduced pressure, dissolved in 200 ml CH2Cl2, extracted from 
the water (4x100 ml). The organic layers were combined, dried over anhydrous Na2SO4 and 
then concentrated under vacuum to obtain the product with cyclen. The residue was 
purified by column chromatography (silica gel, 10% MeOH in CH2Cl2) to give 9 as colorless 
oil (0.34 g, 44%). 1H NMR (CDCl3, 250 MHz), δ (ppm): 2.20-3.02 (m, 18H); 3.69 (s, 3H); 4.36 
(br s, 1H); 5.02 (s, 2H); 5.07-5.25 (m, 4H); 7.25-7.40 (m, 5H). 13C NMR (CDCl3, 62.9 MHz), δ 
(ppm) 43.5; 52.5; 53.2; 53.7; 53.9; 55.0; 59.9; 66.3; 127.7; 128.9; 132.1; 134.2; 161.4; 176.8. ESI-
HRMS (+): calcd C20H33N5O4: m/z 408.2605 (M+H)+; found 408.2607 (M+H)+.  
[4,7-Bis-butoxycarbonylmethyl-10-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxopropyl -
1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid tert-butyl ester (10). A solution of compound 9 
(4.1 g, 10.1 mmol) and sodium carbonate (6.4 g, 60.0 mmol) was added in 70 ml MeCN (dry) 
and heated at 60 °C for 1 h. The reaction mixture was cooled and tert–butylbromoacetate (5.29 
ml, 27.1 mmol) in MeCN (25 ml) was added dropwise. The mixture was then refluxed for 6 h. 
It was then filtered through a G-4 sintered funnel, washed with MeCN and concentrated 
under vacuum. The obtained residue was taken in CH2Cl2 (100 ml) and extracted with water 
(2x50 ml). The organic layer was dried over anhydrous Na2SO4 and concentrated to yellow oil. 
The residue was purified by column chromatography (silica gel, 5% MeOH in CH2Cl2) to give 
10 as light yellow solid (3.5 g, 72%). 1H NMR (CDCl3, 250 MHz), δ (ppm): 1.32 (s, 9H); 1.39 (s, 
18H); 1.83-2.56 (m, 8H); 2.60-3.50 (m, 16H); 3.66 (s, 3H); 4.47 (br s, 1H); 4.71 (br s, 1H); 5.24 (s, 
2H); 7.16-7.42 (m, 5H). 13C NMR (CDCl3, 62.9 MHz), δ (ppm): 27.8; 28.0; 50.3; 50.5; 51.3; 52.3; 
52.6; 53.3; 55.5; 56.1; 56.5; 66.9; 82.1; 82.4; 127.7; 127.9; 128.3; 135.9; 157.0; 171.8; 172.7; 173.1. ESI-
HRMS (+): calcd C38H63N5O10: m/z 750.4647 (M+H)+; found 751.4641 (M+H)+. 
2-(benzyloxycarbonylamino)-3-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)propanoic acid (11). A solution of compound 10 (0.1 g, 0.13 
mmol) was stirred in 7 mL of THF:MeOH:water (3:2:2) at 0-5˚C for 15 min and then LiOH 
(6.5 mg, 0.27 mmol) was added. The reaction mixture was stirred for 2 h at room 
temperature. The progress of the reaction was checked by ESI-MS. After completion, the 
reaction mixture was concentrated under reduced pressure and 11 was obtained as white 
powder (0.76 g, 64%). 1H NMR (CDCl3, 250 MHz), δ (ppm): 1.32 (s, 9H); 1.39 (s, 18H); 1.83-
2.56 (m, 8H); 2.60-3.50 (m, 16H); 4.47 (br s, 1H); 4.71 (br s, 1H); 5.24 (s, 2H); 7.16-7.42 (m, 5H). 
13C NMR (CDCl3, 62.9 MHz), δ (ppm): 27.8; 28.0; 50.3; 50.5; 52.3; 52.6; 53.3; 55.5; 56.1; 56.5; 
66.9; 82.1; 82.4; 127.7; 127.9; 128.3; 135.9; 157.0; 171.8; 172.7; 173.1. ESI-MS (+): calcd 
C37H61N5O10: m/z 736.9 (M+H)+; found 737.1 (M+H)+. 
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[4,7-Bis-butoxycarbonylmethyl-10-(2-(benzyloxycarbonylamino)-3-((R)-5-(tert-
butoxycarbonylamino)-6-methoxy-6-oxohexylamino)-3-oxopropyl-1,4,7,10-tetraaza-
cyclododec-1-yl]-acetic acid tert-butyl ester (12). Compound 11 (0.29 g, 0.4 mmol) was 
dissolved in DMF (5 ml, dry) and NMM (0.1 ml, 0.9 mmol), EDC (0.086 g, 0.44 mmol) and 
(R)-methyl 6-amino-2-(tert-butoxycarbonylamino)hexanoate (0.16 mmol, 0.6 mmol) were 
added under N2 atmosphere. The reaction mixture was stirred at 60°C for 1h. Thereafter, 
HOBt (0.06 g, 0.44 mmol) was added and the heating was continued for 3 h. DMF was 
evaporated under reduced pressure and the obtained residue was dissolved in EtOAc. The 
organic layer was washed with water, dried under anhydrous Na2SO4, and concentrated 
under reduced pressure to obtain crude yellowish residue. This was purified by column 
chromatography (silica gel, 5% MeOH in CH2Cl2) to obtain 12 as yellowish solid (46%, 0.18 
g). 1H NMR (300 MHz, CDCl3), δ (ppm): 1.20 - 1.54 (m, 38 H), 1.54 - 1.88 (m, 5 H), 1.87 - 2.65 
(m, 9 H), 2.64 - 3.12 (m, 8 H), 3.12 - 3.52 (m, 6 H), 3.69 - 3.81 (m, 3 H), 4.15 - 4.32 (m, 1 H), 4.67 
(br. s., 1 H), 4.91 - 5.37 (m, 2 H), 7.19 - 7.44 (m, 5 H). 13C NMR (75 MHz, CDCl3), δ (ppm): 
22.7, 27.8, 27.9, 28.0, 28.2, 28.8, 31.9, 38.8, 49.9, 52.0, 53.3, 53.5, 55.4, 56.3, 56.4, 66.1, 79.4, 81.8, 
81.9, 82.3, 127.3, 127.4, 128.1, 136.8, 155.4, 157.0, 171.8, 172.0, 173.3. ESI-MS (+): calcd  
C49H83N7O13: m/z 978.6 (M+H)+; found 978.5 (M+H)+. 
[4,7-Bis-butoxycarbonylmethyl-10-(2-amino-3-((R)-5-(tert-butoxycarbonylamino)-6-
methoxy-6-oxohexylamino)-3-oxopropyl-1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid tert-
butyl ester (13). Compound 12 (0.05 g, 0.05 mmol) was dissolved in ethanol (10 ml) and Pd-C 
(0.005 g, 10% w/w) was suspended. The mixture was stirred in a Parr aparatus under H2 
atmosphere (3 atm) for 4 h. The solvent was evaporated under reduced pressure to obtain the 
product 13 as yellowish oil in quantitative yield. 1H NMR (300 MHz, CDCl3), δ (ppm): 1.18 - 
1.36 (m, 5 H), 1.36 - 1.41 (m, 11 H), 1.41 - 1.46 (m, 23 H), 1.49 - 1.58 (m, 2 H), 1.58 - 1.67 (m, 1 H), 
1.69 - 1.85 (m, 1 H), 1.93 - 2.35 (m, 4 H), 2.42 - 2.77 (m, 6 H), 2.76 - 3.02 (m, 6 H), 3.08 - 3.39 (m, 7 
H), 3.40 - 3.53 (m, 1 H), 3.68 (s, 3 H), 4.15 - 4.21 (m, 1 H). 13C NMR (75 MHz, CDCl3), δ (ppm): 
22.7, 27.9, 28.1, 28.3, 28.8, 32.0, 39.3, 49.9, 51.2, 52.2, 53.5, 55.4, 56.8, 57.8, 79.6, 81.6, 81.9, 82.5, 
155.5, 167.67, 167.75, 170.7, 173.4. ESI-MS (+): calcd C41H77N7O11: m/z 844.6 (M+H)+; found 844.5 
(M+H)+.  
[4,7-Bis-carboxymethyl-10-(3-((R)-5-amino-5-carboxypentylamino)-3-oxo-2-(5-((3aS,4S,6aR)-
2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)propyl)-1,4,7,10-tetraaza-
cyclododec-1-yl]-acetic acid (L2). Compound 13 (0.045 g, 0.053 mmol) was dissolved in 
anhydrous DMF (2 ml) and HATU (0.022 g, 0.058 mmol) and DIPEA (0.019 ml, 0.1 mmol) 
were added under inert atmosphere. The reaction mixture was stirred at room temperature 
for 18 h. The formation of 14 was confirmed by ESI-MS, the solvent was evaporated under 
reduced pressure and the residue was redissolved in ethylacetate and washed with water. 
The collected organic layer was dried with anhydrous Na2SO4 and evaporated under 
reduced pressure till dry. The residue was subjected to global deprotection. Methyl ester 
hydrolysis was carried out by LiOH (0.13 mmol, 0.005 g) in THF:MeOH:H2O (3:3:2) for 2h. 
The solvent was evaporated and the residue dissolved in TFA (10 ml, neat) to hydrolyze 
tert-Bu-ester and deprotect the Boc group. TFA was evaporated under reduced pressure to 
obtain a yellowish residue. The residue was redissolved in water, the pH was increased to 7 
and thereafter purified by RP-HPLC (tR = 4.8) to obtain the product, L2, as a yellow sticky 
solid. 1H NMR (300 MHz, D2O), δ (ppm): 1.33 (br. s., 4 H), 1.42 - 1.60 (m, 5 H), 1.60 - 1.72 (m, 
1 H), 1.74 - 1.92 (m, 2 H), 2.16 - 2.38 (m, 2 H), 2.65 - 2.96 (m, 6 H), 2.98 - 3.36 (m, 13 H), 3.41 - 
3.60 (m, 3 H), 3.62 (s, 1 H), 3.64 - 3.82 (m, 4 H), 3.84 - 4.03 (m, 3 H), 4.25 - 4.33 (m, 1 H), 4.36 
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(dd, J=7.88, 4.58 Hz, 1 H), 4.53 (dd, J=7.63, 5.09 Hz, 1 H). 13C NMR (75 MHz, D2O), δ (ppm): 
20.8, 20.9, 23.9, 24.0, 26.9, 27.2, 27.3, 29.0, 34.0, 38.1, 38.9, 46.8, 48.5, 49.9, 51.5, 52.4, 52.8, 53.2, 
54.58, 54.68, 55.1, 55.8, 59.4, 61.2, 149.9, 164.5, 173.0, 176.8. Compound 14: ESI-MS (+): calcd 
C51H91N9O13S: m/z 1070.6 (M+H)+; found 1070.5 (M+H)+. Compound L2: ESI-MS (-): calcd 
C33H57N9O11S: m/z 786.4 (M-H)-; found 786.4 (M-H)-. 
General Preparation of Gadolinium Complexes of L1 and L2. Gadolinium complexes of L1 
and L2 were prepared from corresponding solutions of the ligands (1 eq) and solutions of 
GdCl3.6H2O (1.1 eq). The reaction mixture was stirred at 60°C for 20 h. The pH was 
periodically checked and adjusted to 6.5 using solutions of NaOH (1 M) and HCl (1 N) as 
needed. After completion, the reaction mixture was cooled and passed through chelex-100 
to trap free Gd3+ ions, and the Gd-loaded complexes were eluted. The absence of free Gd3+ 
was checked with xylenol orange indicator. The fractions were lyophilized to obtain off-
white solids. These complexes were characterized by ESI-MS in positive and negative mode 
and the appropriate isotope pattern distributions for Gd3+ were recorded. 
[Gd.L1]. ESI-MS (+): calcd C35H58155GdN9O11S: m/z 971.3 [M+H]+; found 971.4 [M+H]+, r1p = 
5.52 [mM-1s-1] at 300 MHz. 
[Gd.L2]. ESI-MS (+): calcd C33H54155GdNaN9O11S: m/z 965.2 [M+Na]+; found 965.3 [M+Na]+, 
r1p = 7.27 [mM-1s-1] at 300 MHz. 
4.6 In vitro cell studies of [Gd.L
1
], [Gd.L
2
] and [Fluo-L
1
] 
4.6.1 Cell culture 
N18 mouse neuroblastoma cells (kind gift of Prof. Bernd Hamprecht, University of 
Tübingen, Germany) were cultured as a monolayer at 37°C with 5% CO2 in antibiotic free 
Dulbecco’s Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 4 mM L-glutamine, (all purchased from Biochrom AG). Cells were passaged by 
trypsinization with trypsin/EDTA 0.05/0.02% (w/v) in phosphate-buffered saline (PBS; 
Biochrom AG, Germany) for 5 minutes every second to third day. Prior to experiments the 
serum content was stepwise reduced to 0.625% to induce morphological differentiation.  
4.6.2 Preparation of labeling solutions 
CA were dissolved in water and the concentration was determined by BMS measurement 
for [Gd.L1] and [Gd.L2] or by absorbance of fluorescein for [Fluo.L1]. For each experiment, 
dilutions from these stocks were freshly made in incubation medium and thoroughly mixed 
at indicated concentrations.  
4.6.3 Live cell imaging 
Microscopy was done in single channel Ibidi slides (Ibidi GmbH, Germany) by inoculation 
of N18 cells (3 x 105 cells/ml) cultured in Dulbecco’s Modified Eagle's Medium 
supplemented with 0.625% fetal bovine serum and 4 mM L-glutamine (all purchased from 
Biochrom AG). After reaching 70-80% confluency, cells were incubated with 50 µM of 
[Fluo.L1] for 12 hours. Before washing cells were incubated with nuclear stain Bisbenzimid 
33342 (Hoechst 33342) for 5 min. Afterwards, extracellular fluorescence was quenched by 
the addition of ice-cold Trypan Blue for 3 min (Rennert et al.). After repeated cell washings 
with Hank’s buffered saline solution (HBSS, Biochrom AG, Germany), fluorescence 
microscopy was performed on a Zeiss Axiovert 200M (Carl Zeiss AG, Germany) with a 
Plan-Apochromat 63X objective to observe the cellular localization of [Fluo.L1]. The imaging 
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conditions were kept constant for the observation of different samples. Cellular localization 
and distribution of [Fluo.L1] was determined by irradiating with blue light (470 nm) and 
observing at 525 nm, and nuclear labeling by Hoechst was imaged at 460 nm. Also phase 
contrast images with Differential Interference Contrast (DIC) of the same area were made to 
detect if the cells maintain their normal morphology in the presence of compound. 
4.6.4 MR measurement in cells 
For MR imaging, serum deprived N18 cells (1.25% FBS) were cultured in 175 cm2 tissue 
culture flasks and labeled with 20 or 40 µM of [Gd.L1] or [Gd.L2] in HBSS/10mM HEPES for 
6h. After incubation samples of the treatment solution were collected, if required 
centrifuged, and 500 µl were used for determination of R1 and R2. Cells were repeatedly 
washed with HBSS, trypsinized, centrifuged and re-suspended in 0.5 ml Eppendorf tubes at 
a cell density of 1 x 107/500µl in complete medium. Cells were allowed to settle before MR 
measurements. Tubes with medium only and cells without CA were used as controls. Two 
tubes of treatment solutions, HBSS/10 mM HEPES as well as of cells for each condition were 
used. Experiments were done at least twice. 
MR imaging of the cell pellets at room temperature (~21 ˚C) was performed in a 3 T (123 
MHz) human MR scanner (MAGNETOM Tim Trio, Siemens Healthcare, Germany), using a 
12-channel RF Head coil and slice selective measurements from a slice with a thickness of  
1 mm positioned through the cell pellet. 
T1 was measured using an inversion-recovery sequence, with an adiabatic inversion pulse 
followed by a turbo-spin-echo readout. Between 10 and 15 images were taken, with the time 
between inversion and readout varying from 23 ms to 3000 ms. With a repetition time of  
10 s, 15 echoes were acquired per scan and averaged six times. For T2, a homewritten spin-
echo sequence was used with echo times varying from 18 ms to 1000 ms in about 10 steps 
and a repetition time of 8 s. Diffusion sensitivity was reduced by minimizing the crusher 
gradients surrounding the refocusing pulse. All experiments scanned 2562 voxels in a field-
of-view of 110 mm in both directions resulting in a voxel volume of 0.43 × 0.43 × 1 mm3. 
Data analysis was performed by fitting to relaxation curves with self-written routines under 
MATLAB 7.1 R14 (The Mathworks Inc., United States). The series of T1 relaxation data were 
fitted to the following equation. 
T1 series with varying t = TI: S = S0 (1 - exp(-t / T1) + S(TI = 0) exp(-t / T1). 
Nonlinear least-squares fitting of three parameters S0, S(TI = 0), and T1 was done for manually 
selected regions-of-interest with the Trust-Region Reflective Newton algorithm 
implemented in MATLAB. The quality of the fit was controlled by visual inspection and by 
calculating the mean errors and residuals. 
Evaluation of the signal intensities in the T1-weighted MR images were performed in ImageJ 
(http://rsb.info.nih.gov/ij) by defining a circular region of interest (ROI) inside one tube 
image and measuring the mean signal intensity and standard deviation in the included 
voxels. Further statistical analyses were performed in GraphPad Prism 5.03 (GraphPad 
Software, Inc., USA). 
4.7 In vivo rat experiments 
To test whether [Gd.L1], [Gd.L2] and [Fluo.L1] were transported inside cells and could be 
visualized by MR and histological methods, we performed injections of all three compounds 
into the primary motor cortex of 8 albino rats (Sprague Dawley). Three of them (with 
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[Gd.L1]) were sacrificed after 24 h and the other three (one with [Gd.L1] and two with 
[Gd.L2]) were euthanized after 48 h. The remaining two (with [Fluo.L1]) were euthanized 
after 24 h. 
4.7.1 Injections 
All rats were anaesthetized with 2% isoflurane (Abbott) and placed in a stereotaxic frame 
(Kopf Instruments). After additional use of xylocain for local analgesia in the surgery area, a 
craniotomy was performed and a pulled fused silica capillary (ID 50µm; OD 150 µm; tip 
diameter 20-30 µm) was placed in the primary motor cortex at a depth of 1.2 mm below the 
surface. One compound per animal was then injected using a pressure cell containing the 
compound attached to the other end of the fused silica capillary. 100 nl of 4% tracer solution 
was injected at a flow rate of 3.3 nl/min. After injection, the capillary was left in place for 10 
minutes before retracting it stepwise to avoid backflow of the injected solution. 
In some cases we made iontophoretic injections, using borosilicate pipettes with tip 
diameters of 20-25 µm. In case of the injection shown in Fig. 6, injection time was 35 min (7s 
on, 7 s off) with a current of 4 µA. In case of the injection shown in Fig. 7, injection time was 
70 min (7 s on, 7 s off) with a current of 10 µA.  
At the end of the procedure, the animals received an intraperitoneal injection of analgesics 
and antibiotics [5mg/kg Baytril® (Bayer) and 2.5mg/kg Finadyne® (Essex)]. The animals to 
be left for 48 h received another injection of analgesics and antibiotics after 24 h. 
4.7.2 In vivo MRI experiments 
For the MRI experiments, the animals were anaesthetized with 1.5-2% isoflurane and placed 
in a home-made quadrature coil integrated within a stereotaxic animal holder. The head 
holder was adapted with movable bite and ear bars and positioned fixed on a magnet chair. 
This allowed precise positioning of the animal with respect to the coil and the magnet, 
avoiding movement artifacts. Body temperature, heart rate, CO2 and SpO2 were monitored 
throughout the scanning session. We typically scanned the animals before, immediately 
after and 24-48 h after the injection of CAs. One scan session consisted on 5 to 7 scans of 18 
min each. 
Experiments were carried out in a vertical 7T (300 MHz)/60-cm diameter bore magnet 
(Bruker BioSpin, Ettlingen). The saddle coil, which was designed to generate a 
homogeneous field over the whole rat brain, was used to transmit and receive. The MR 
system was controlled by a Bruker BioSpec console (ParaVision 3, 4 and 5 at different time 
periods) running under Linux operating system. We used a Modified Driven Equilibrium 
Fourier Transform (MDEFT) method with MDEFT-preparation (Lee et al., 1995) to obtain T1-
weighted anatomical images. The scan parameters were: TR = 22.2 ms, TE = 4.8 ms, FA = 
20°, ID = 1000 ms and four segments. The geometric parameters of the 3D scans were: 
matrix 192×136×100, FOV = 48×34×25 mm and voxel size 0.25×0.25×0.25 mm. 
The MRI images were analyzed with custom-developed Matlab functions (v7.5.0, 
MathWorks). An automated realignment procedure of SPM (statistical parametric mapping, 
www.fil.ion.ucl.ac.uk) was applied to co-register all scans. For statistical analysis the image 
intensity was normalized to reference signal intensity in the head muscles. Statistical maps 
were generated by implementing a Student's t-test (unpaired) at each voxel comparing brain 
images before and 24-48h after CAs injection. The significant voxels represent the pattern of 
T1-weighted MRI signal enhancement induced by the neuronal transport of CAs. The 
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arbitrary significance threshold was set to P < 0.01 (uncorrected for multiple comparisons) 
for individual voxels, and a minimum cluster size of 3 contiguous voxels constituting at 
least 3% of total number of voxels for a given region of interest (ROI). The same data were 
also tested for lower or higher p-values. 
4.7.3 Perfusion 
After the last MRI session, the animals received a lethal intraperitoneal injection of the 
barbiturate Pentobarbital sodium (Narcoren from Merial; 2.5 ml/kg body weight). After 
cessation of all reflexes, the chest of the animal was opened and 0.4 ml of Heparin-Sodium 
25000 (ratiopharm) was injected into the heart in order to prevent coagulation. Then a 
cannula was inserted and the animal was perfused with iosotonic saline (using NaCl 0.9 E 
from Fresenius) for about 5 minutes and then with the fixative (commercially available 4% 
paraformaldehyde, phosphate buffered; Roti-Histofix 4% from Carl Roth).  
The brain was removed from the skull and kept in the fixative over night. The next day the 
brain was transferred into 30% sucrose in demineralized water and kept there for at least 4 
days until it had sunk. The brain was then sliced into serial sections with a cryotome at a 
thickness of 70 µm. 
4.7.4 Histological procedure 
The protocol for the biotin-avidin reaction largely followed that by Horikawa and 
Armstrong (Horikawa and Armstrong, 1988) with some modifications suggested by Dr. 
Michaela Schweizer (personal communication). In detail: the sections were collected in 
phosphate buffer (PB, 0.1 M; pH 7.3), rinsed again in PB and then transferred into 1% H2O2 
in PB for 1 h, in order to block endogenous peroxidase activity. After rinsing 3 times in PB, 
the sections were kept for 90 min in Triton X-100 (2% in 0.1 M PB from Carl Roth). They 
were then incubated overnight in avidin-conjugated peroxidase (ABC Elite PK 6100 from 
Linaris, 1% in 0.1 M PB: i.e. adding 10 drops per 50 µl of each of the two solutions to 49 ml of 
buffer. Note that the ABC-mixture must stand for 30 min before use). On the next day, the 
sections were rinsed 2 x 10 min in PB (0.1 M) and then 2 x 10 min in Tris/HCl at pH 7.9 
(using a 0.1 M solution of tris-(hydroxymethyl)-aminomethane and pH adjusted to 7.9 with 
HCl). The sections were then transferred into a solution of diamino benzidine (DAB) and 
H2O2 (DAB tablet were dissolved in demineralized water) for 30 – 45 min. After washing 
three times in Tris/HCl, the sections were transferred into 0.05 M PB and mounted on 
electrostatic slides (Superfrost Plus, Menzel, ThermoScientific), air-dried over night, 
dehydrated in ethanol (70%, 2 x 99%, 1 x 100% ethanol, 2 x terpineole and 2 x xylene), and 
covered in Eukitt or DePeX.  
5. Acknowledgement  
The authors thank Prof. Bernd Hamprecht, for the kind gift of the N18 mouse 
neuroblastoma cell line. The authors also thank Dr. Hellmut Merkle for providing the rf-coil 
for in vivo MRI imaging. This work was supported by the Max-Planck Society and the Hertie 
Foundation. S.C. acknowledges the support of the Human Frontiers Science Program 
Organization and the Ministry of Science and Innovation of Spain (BFU2009-09938) and the 
Consolider-Ingenio 2010 Program (CSD2007-0023). A.M. acknowledges the support of the 
EC for a Marie Curie IEF (PIEF-GA-2009-237253).  
www.intechopen.com
 
Neuroimaging – Methods 
 
202 
6. References  
Aime, S., Botta, M., Parker, D., and Williams, J.A.G. (1996). Extent of hydration of 
octadentate lanthanide complexes incorporating phosphinate donors: Solution 
relaxometry and luminescence studies. Journal of the Chemical Society-Dalton 
Transactions, 17-23. 
Baur, B., Suormala, T., and Baumgartner, E.R. (2002). Biocytin and biotin uptake into NB2a 
neuroblastoma and C6 astrocytoma cells. Brain Res 925, 111-121. 
Bickel, U., Yoshikawa, T., and Pardridge, W.M. (2001). Delivery of peptides and proteins 
through the blood-brain barrier. Adv Drug Deliv Rev 46, 247-279. 
Botta, M. (2000). Second coordination sphere water molecules and relaxivity of 
gadolinium(III) complexes: Implications for MRI contrast agents. European Journal 
of Inorganic Chemistry, 399-407. 
Canals, S., Beyerlein, M., Keller, A.L., Murayama, Y., and Logothetis, N.K. (2008). Magnetic 
resonance imaging of cortical connectivity in vivo. Neuroimage 40, 458-472. 
Canals, S., Beyerlein, M., Merkle, H., and Logothetis, N.K. (2009). Functional MRI evidence 
for LTP-induced neural network reorganization. Curr Biol 19, 398-403. 
Cao, R., Gu, Z., Hsu, L., Patterson, G.D., and Armitage, B.A. (2003). Synthesis and 
characterization of thermoreversible biopolymer microgels based on hydrogen 
bonded nucleobase pairing. J Am Chem Soc 125, 10250-10256. 
Caravan, P., Ellison, J.J., McMurry, T.J., and Lauffer, R.B. (1999). Gadolinium(III) Chelates as 
MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev 99, 2293-
2352. 
Caswell, K.K., Wilson, J.N., Bunz, U.H., and Murphy, C.J. (2003). Preferential end-to-end 
assembly of gold nanorods by biotin-streptavidin connectors. J Am Chem Soc 125, 
13914-13915. 
Chandra, S.V., Shukla, G.S., Srivastava, R.S., Singh, H., and Gupta, V.P. (1981). An 
exploratory study of manganese exposure to welders. Clin Toxicol 18, 407-416. 
Chklovskii, D.B., Mel, B.W., and Svoboda, K. (2004). Cortical rewiring and information 
storage. Nature 431, 782-788. 
Heller, A.J., Stanley, C., Shaia, W.T., Sismanis, A., Spencer, R.F., and Wolf, B. (2002). 
Localization of biotinidase in the brain: implications for its role in hearing loss in 
biotinidase deficiency. Hear Res 173, 62-68. 
Horikawa, K., and Armstrong, W.E. (1988). A versatile means of intracellular labeling: 
injection of biocytin and its detection with avidin conjugates. J Neurosci Methods 
25, 1-11. 
Hymes, J., and Wolf, B. (1996). Biotinidase and its roles in biotin metabolism. Clin Chim 
Acta 255, 1-11. 
King, M.A., Louis, P.M., Hunter, B.E., and Walker, D.W. (1989). Biocytin: a versatile 
anterograde neuroanatomical tract-tracing alternative. Brain Res 497, 361-367. 
Kita, H., and Armstrong, W. (1991). A biotin-containing compound N-(2-
aminoethyl)biotinamide for intracellular labeling and neuronal tracing studies: 
comparison with biocytin. J Neurosci Methods 37, 141-150. 
Kobbert, C., Apps, R., Bechmann, I., Lanciego, J.L., Mey, J., and Thanos, S. (2000). Current 
concepts in neuroanatomical tracing. Prog Neurobiol 62, 327-351. 
Koretsky, A.P., and Silva, A.C. (2004). Manganese-enhanced magnetic resonance imaging 
(MEMRI). NMR Biomed 17, 527-531. 
www.intechopen.com
Biocytin-Based Contrast Agents for Molecular Imaging:  
An Approach to Developing New In Vivo Neuroanatomical Tracers for MRI 
 
203 
Lapper, S.R., and Bolam, J.P. (1991). The anterograde and retrograde transport of 
neurobiotin in the central nervous system of the rat: comparison with biocytin. J 
Neurosci Methods 39, 163-174. 
Lee, J.H., Garwood, M., Menon, R., Adriany, G., Andersen, P., Truwit, C.L., and Ugurbil, K. 
(1995). High contrast and fast three-dimensional magnetic resonance imaging at 
high fields. Magn Reson Med 34, 308-312. 
Leergaard, T.B., Bjaalie, J.G., Devor, A., Wald, L.L., and Dale, A.M. (2003). In vivo tracing of 
major rat brain pathways using manganese-enhanced magnetic resonance imaging 
and three-dimensional digital atlasing. Neuroimage 20, 1591-1600. 
Livramento, J.B., Weidensteiner, C., Prata, M.I., Allegrini, P.R., Geraldes, C.F., Helm, L., 
Kneuer, R., Merbach, A.E., Santos, A.C., Schmidt, P., et al. (2006). First in vivo MRI 
assessment of a self-assembled metallostar compound endowed with a remarkable 
high field relaxivity. Contrast Media Mol Imaging 1, 30-39. 
Marchisio, P.C., Weber, K., and Osborn, M. (1979). Identification of multiple microtubule 
initiating sites in mouse neuroblastoma cells. Eur J Cell Biol 20, 45-50. 
McMillan, D.E. (1999). A brief history of the neurobehavioral toxicity of manganese: some 
unanswered questions. Neurotoxicology 20, 499-507. 
Mishra, A., Dhingra, K., Schu ̈z, A., Logothetis, N.K., and Canals, S. (2009). Improved 
Neuronal Tract Tracing with Stable Biocytin-Derived Neuroimaging Agents. ACS 
Chemical Neuroscience 1, 129-138. 
Mock, D.M., Lankford, G.L., Widness, J.A., Burmeister, L.F., Kahn, D., and Strauss, R.G. 
(1999). Measurement of circulating red cell volume using biotin-labeled red cells: 
validation against 51Cr-labeled red cells. Transfusion 39, 149-155. 
Murayama, Y., Weber, B., Saleem, K.S., Augath, M., and Logothetis, N.K. (2006). Tracing 
neural circuits in vivo with Mn-enhanced MRI. Magn Reson Imaging 24, 349-358. 
Pal, P.K., Samii, A., and Calne, D.B. (1999). Manganese neurotoxicity: a review of clinical 
features, imaging and pathology. Neurotoxicology 20, 227-238. 
Pautler, R.G., Silva, A.C., and Koretsky, A.P. (1998). In vivo neuronal tract tracing using 
manganese-enhanced magnetic resonance imaging. Magn Reson Med 40, 740-748. 
Pispa, J. (1965). Animal biotinidase. Ann Med Exp Biol Fenn 43, Suppl 5:1-39. 
Pope, S.J., Kenwright, A.M., Heath, S.L., and Faulkner, S. (2003). Synthesis and luminescence 
properties of a kinetically stable dinuclear ytterbium complex with differentiated 
binding sites. Chem Commun (Camb), 1550-1551. 
Rivera, V.R., Merrill, G.A., White, J.A., and Poli, M.A. (2003). An enzymatic 
electrochemiluminescence assay for the lethal factor of anthrax. Anal Biochem 321, 
125-130. 
Saleem, K.S., Pauls, J.M., Augath, M., Trinath, T., Prause, B.A., Hashikawa, T., and 
Logothetis, N.K. (2002). Magnetic resonance imaging of neuronal connections in the 
macaque monkey. Neuron 34, 685-700. 
Sloot, W.N., and Gramsbergen, J.B. (1994). Axonal transport of manganese and its relevance 
to selective neurotoxicity in the rat basal ganglia. Brain Res 657, 124-132. 
Suchy, S.F., McVoy, J.S., and Wolf, B. (1985). Neurologic symptoms of biotinidase deficiency: 
possible explanation. Neurology 35, 1510-1511. 
Tjalve, H., Mejare, C., and Borg-Neczak, K. (1995). Uptake and transport of manganese in 
primary and secondary olfactory neurones in pike. Pharmacol Toxicol 77, 23-31. 
www.intechopen.com
 
Neuroimaging – Methods 
 
204 
Tsao, C.Y., and Kien, C.L. (2002). Complete biotinidase deficiency presenting as reversible 
progressive ataxia and sensorineural deafness. J Child Neurol 17, 146. 
Van der Linden, A., Verhoye, M., Van Meir, V., Tindemans, I., Eens, M., Absil, P., and 
Balthazart, J. (2002). In vivo manganese-enhanced magnetic resonance imaging 
reveals connections and functional properties of the songbird vocal control system. 
Neuroscience 112, 467-474. 
Watanabe, T., Frahm, J., and Michaelis, T. (2004). Functional mapping of neural pathways in 
rodent brain in vivo using manganese-enhanced three-dimensional magnetic 
resonance imaging. NMR Biomed 17, 554-568. 
Weizmann, Y., Patolsky, F., Katz, E., and Willner, I. (2003). Amplified DNA sensing and 
immunosensing by the rotation of functional magnetic particles. J Am Chem Soc 
125, 3452-3454. 
Wilbur, D.S., Hamlin, D.K., Vessella, R.L., Stray, J.E., Buhler, K.R., Stayton, P.S., Klumb, 
L.A., Pathare, P.M., and Weerawarna, S.A. (1996). Antibody fragments in tumor 
pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant 
streptavidin and avidin. Bioconjug Chem 7, 689-702. 
Wirsig-Wiechmann, C.R. (1994). Biocytin: a neuronal tracer compatible with rapid 
decalcification procedures. J Neurosci Methods 51, 213-216. 
Zaffanello, M., Zamboni, G., Fontana, E., Zoccante, L., and Tato, L. (2003). A case of partial 
biotinidase deficiency associated with autism. Child Neuropsychol 9, 184-188. 
www.intechopen.com
Neuroimaging - Methods
Edited by Prof. Peter Bright
ISBN 978-953-51-0097-3
Hard cover, 358 pages
Publisher InTech
Published online 17, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Neuroimaging methodologies continue to develop at a remarkable rate, providing ever more sophisticated
techniques for investigating brain structure and function. The scope of this book is not to provide a
comprehensive overview of methods and applications but to provide a 'snapshot' of current approaches using
well established and newly emerging techniques. Taken together, these chapters provide a broad sense of
how the limits of what is achievable with neuroimaging methods are being stretched.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Anurag Mishra, Kirti Dhingra, Ritu Mishra, Almut Schüz, Jörn Engelmann, Michael Beyerlein, Santiago Canals
and Nikos K. Logothetis (2012). Biocytin-Based Contrast Agents for Molecular Imaging: An Approach to
Developing New In Vivo Neuroanatomical Tracers for MRI, Neuroimaging - Methods, Prof. Peter Bright (Ed.),
ISBN: 978-953-51-0097-3, InTech, Available from: http://www.intechopen.com/books/neuroimaging-
methods/biocytin-based-contrast-agents-for-molecular-imaging-an-approach-to-developing-new-in-vivo-
neuroanat
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
